Compare Pfizer Inc (PFE) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Royal Caribbean Cruises Ltd — how do they compare? Pfizer Inc trades at $27.83 (market cap $159.59B), while Royal Caribbean Cruises Ltd trades at $284.94 (market cap $75.51B). The key difference: Pfizer Inc is far larger — about 2.1× Royal Caribbean Cruises Ltd's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| PFE | RCL | |
|---|---|---|
Market Cap | $159.59B | $75.51B |
Volume | 30,937,010 | 2,408,997 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $348.03 |
52-Week Low | $23.67 | $230.30 |
Typical Hold Time | 158 Days | 85 Days |
Enterprise Value | $211.09B | $98.15B |
Dividend Yield | 6.14% | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Royal Caribbean (RCL) trades at $282.36, down 2.25% today but maintains strong fundamentals with robust revenue growth from $8.8B in 2022 to $17.9B in 2025 and net income surging to $4.27B. The technical picture is bullish with support at $280 and resistance at $287, while analyst consensus favors Buy ratings (51%) with a $346.67 price target. Recent news highlights the $3B Sandals Resorts stake expansion and positive industry momentum from Carnival's strong results.
RCL presents a compelling growth story with expanding margins and strategic diversification, though elevated debt levels and fuel cost sensitivity pose risks. The stock's current valuation at 17.44x P/E offers room for upside relative to analyst targets, supported by consistent earnings beats and bullish institutional sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
